Kaplan Lab


Kaplan GB, Leite-Morris KA, Wang L, Rumbika KK, Heinrichs SC, Zeng X, Wu L, Arena DT, Teng YD. Pathophysiological bases of comorbidity: Traumatic brain injury and post-traumatic stress disorder. Journal of neurotrauma. 35(2):210-25, 2018

Kobrin KL, Arena DT, Heinrichs SC, Nguyen OH, Kaplan GB. Dopamine D1 receptor agonist treatment attenuates extinction of morphine conditioned place preference while increasing dendritic complexity in the nucleus accumbens core. Behavioural brain research. 322:18-28, 2017

Kobrin KL, Moody O, Arena DT, Moore CF, Heinrichs SC, Kaplan GB. Acquisition of morphine conditioned place preference increases the dendritic complexity of nucleus accumbens core neurons. Addiction biology. 21(6):1086-96, 2016

Liverant GI, Sloan DM, Pizzagalli DA, Harte CB, Kamholz BW, Rosebrock LE, Cohen AL, Fava M, Kaplan GB. Associations among smoking, anhedonia, and reward learning in depression. Behavior therapy. 45(5):651-63, 2014

Leite-Morris KA, Kobrin KL, Guy MD, Young AJ, Heinrichs SC, Kaplan GB. Extinction of opiate reward reduces dendritic arborization and c-Fos expression in the nucleus accumbens core. Behavioural brain research. 263:51-9. 2014

Heinrichs SC, Leite-Morris KA, Rasmusson AM, Kaplan GB. Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. Neuroscience letters. 552:108-13, 2013

Heinrichs SC, Leite-Morris KA, Guy MD, Goldberg LR, Young AJ, Kaplan GB. Dendritic structural plasticity in the basolateral amygdala after fear conditioning and its extinction in mice. Behavioural brain research. 248:80-4, 2013

Dhonnchadha BN, Lin A, Leite-Morris KA, Kaplan GB, Man HY, Kantak KM. Alterations in expression and phosphorylation of GluA1 receptors following cocaine-cue extinction learning. Behavioural brain research. 238:119-23, 2013

Dhonnchadha BN, Lovascio BF, Shrestha N, Lin A, Leite-Morris KA, Man HY, Kaplan GB, Kantak KM. Changes in expression of c-Fos protein following cocaine-cue extinction learning. Behavioural brain research. 234(1):100-6, 2012

Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, AhnAllen CG. Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine & Tobacco Research. 2012 Apr 19;15(1):121-9, 2012

Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology. 217(2):279-87, 2011

Kaplan GB, Leite-Morris KA, Fan WY, Young AJ, Guy MD. Opiate sensitization induces FosB/ΔFosB expression in prefrontal cortical, striatal and amygdala brain regions. PLoS One 6(8):e23574, 2011

Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology, 217(2):279-87, 2011

Kaplan GB and Moore KA. The use of cognitive enhancers in animal models of fear extinction.  Pharmacol Biochem Behav, 99:217-28, 2011

Kaplan GB, Heinrichs S, Carey RC.  Treatment of addiction and anxiety using extinction approaches: neural mechanisms and their treatment implications, Pharmacol Biochem Behav, Pharmacol Biochem Behav 97:619–625, 2011

Kaplan GB, Vasterling JJ, and Vedak PC.  Brain derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behavioural Pharmacology 21(5-6):427-37, 2010

Sirota AD, MacKinnon SV, Martin RA, Eaton CA, Kaplan GB, Monti PM, Tidey JW, Swift RM, Rohsenow DJ. Intolerance for smoking abstinence questionnaire: psychometric properties and relationship to tobacco dependence and abstinence. Addictive Behaviors, 35(7):686-93, 2010

Heinrichs S, Leite-Morris KA, Carey RC, Kaplan GB. Baclofen enhances the extinction of opiate conditioned place preference, Behavioural Brain Res, 207:353–359, 2010

Kaplan GB, Leite-Morris KA, Klufas M, Fan W. Intra-VTA adenosine A1 receptor activation blocks morphine stimulation of motor behavior and cortical and limbic Fos immunoreactivity, Eur J Pharmacol 602(2-3):268-276, 2009

Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Adolpho AB. Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia versus controls, Nicotine Tobacco Res 10:1047-1056, 2008

Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R; VA CSP No. 425 Study Team (includes Kaplan GB).  Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, “Naltrexone in the treatment of alcoholism".  Alcohol Clin Exp Res 32:85-91, 2008 

Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH; VA Cooperative Study #425 Study Group (includes Kaplan GB).  Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.  Alcohol Clin Exp Res 31:555-63, 2007

Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, Kaplan GB. High dose transdermal nicotine and naltrexone:  effects on nicotine withdrawal, urges, smoking, and effects of smoking. Experimental and Clinical Psychopharmacology 15:81-92, 2007

Kaplan GB, Phillips KA, Vaccaro A, Eisen JL, Posternak MA, MacAskill HS. Assessment of insight into delusionality in schizophrenia and schizoaffective disorder using the Brown Assessment of Beliefs Scale. Schizophrenia Res 82:279-281, 2006

Epstein-Lubow G, Hochstadt J, Lieberman P, Kaplan GB. Speech production in schizophrenia: a pilot investigation of voice onset time. Schizophrenia Res 82:267-9, 2006

Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls, Drug Alcohol Depend 80:259-65, 2005.

Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Subjective and physiological responses to smoking cues in smokers with schizophrenia, Nicotine Tobacco Res 7:421–429, 2005

Kranzler HR, Wesson DR, Billot L and the Drug Abuse Sciences Naltrexone Depot Study Group (includes Kaplan GB). Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled study. Alcoholism: Clin Exp Res 28:1051-1059, 2004.

Turalba AV, Leite-Morris KA, Kaplan GB.  Antipsychotic drug treatment regulates cAMP-dependent protein kinase and phosphorylation of cyclic AMP response-element binding protein in cortical and striatal regions. Neurosci Lett 357:53-57, 2004

Leite-Morris KA, Fukudome EY, Shoeb M, Kaplan GB.  GABAB receptor activation in the ventral tegmental area blocks opiate-induced motor stimulation and sensitization. J Pharmacol Exp Ther 308:667-678, 2004

Kaplan GB, McRoberts L, Smokler, H. Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder. J Clin Psychopharmacol 24:574, 2004

Kaplan GB, Leite-Morris KA, Joshi M, Shoeb M, Carey R. Baclofen inhibits opiate-induced conditioned place preference and associated induction of Fos in cortical and limbic regions. Brain Res 987: 122-125, 2003

Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J; VA Naltrexone Study Group 425 (includes Kaplan GB). Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003 Sep-Oct;6(5):566-73.

Leite-Morris KA, Fukudome EY, Kaplan GB.  Opiate-induced motor stimulation is regulated by gamma-aminobutyric acid type B receptors found in the ventral tegmental area. Neurosci Lett 317: 119-122, 2002

Krystal JH, Cramer JA, Krol WF, Kirk MA, Rosenheck RA, for the Veterans Affairs Naltrexone Cooperative Study 425 Group (includes Kaplan GB). Naltrexone in the treatment of alcohol dependence.  New Engl J Med 345: 1734-1739, 2001

Pande AC, Crockatt JG, Janney CA, Tsarouch G, Werth JL, Gabapentin Bipolar Study Group (includes Kaplan GB).  Gabapentin in Bipolar Disorder: a placebo-controlled trial of adjunctive medication. Bipolar Disorders 2:249-255, 2000

Rohsenow DJ, Monti PM, Hutchinson KE, Swift RM, Colby SM, Kaplan GB.  Naltrexone’s effects on reactivity to alcohol cues among alcoholic men. J Abnormal Psychology 109:738-742, 2000

Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RS. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single-dose of alprazolam.   J Clin Psychopharmacol 20: 338-346, 2000

Kaplan GB, Leite-Morris KA, Keith DJ.  Differential effects of chronic treatment with typical and atypical antipsychotic drugs on G proteins and adenylyl cyclase.  Neurosci Lett 273:147-150, 1999

Kaplan GB, Bharmal NP, Leite-Morris KA, Adams, WR.   Role of adenosine A1 and A2A receptors in the alcohol withdrawal syndrome.   Alcohol 19:157-162, 1999

Weisberg SP, Kaplan GB.  Adenosine receptor antagonists inhibit the development of morphine-induced sensitization in the C57BL/6 mouse.  Neurosci Lett 264:1-4, 1999

Kaplan GB, Coyle TS.  Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation.  Eur J Pharmacol 362:1-8, 1998

Leite-Morris KA, Kaplan GB, Smith JG, Sears MT.  Alterations in G proteins and adenylyl cyclase in brain regions of caffeine-tolerant and -dependent mice. Brain Res 804:52-62, 1998.

Kaplan GB, Leite-Morris KA, Sethi RK, McClelland EG.  Regulation of G protein-mediated adenylyl cyclase activity in striatum and cortex of opiate-dependent and opiate-withdrawing mice.  Brain Res 788:104-110, 1998

Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RS.   Single-dose alprazolam pharmacokinetics and pharmacodynamics in the elderly. J Clin Pharmacol 38:14-21, 1998

Kaplan GB, Leite-Morris KA.  Up-regulation of adenosine transporter binding sites in striatum and hypothalamus of morphine tolerant mice. Brain Res 763:215-220, 1997

Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RS.   Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37:693-703, 1997 

Kaplan GB, Sears MT.  Adenosine receptor agonists attenuate and antagonists excerbate opiate withdrawal signs. Psychopharmacology 123:64-70, 1996

Kaplan GB, Leite-Morris KA, Sears MT.  Alterations in adenosine A1 receptors in morphine dependence.  Brain Res 657: 347-350, 1994

Kaplan GB, Kent MA, Cotreau-Bibbo MM, Greenblatt DJ.  Caffeine treatment and withdrawal in mice: Relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding.  J Pharmacol Exp Ther 266:1563-1572, 1993

Kaplan GB, Cotreau MM, Greenblatt DJ.  Effects of benzodiazepine administration on A1 adenosine receptor binding in vivo and ex vivo.  J Pharm Pharmacol 44:700-703, 1992

Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G, Shader RI.  Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy.  Neuropsychopharmacology 6:145-153, 1992

Kaplan GB, Tai NT, Greenblatt DJ, Shader RI.  Caffeine-induced behavioral stimulation is dose- and concentration-dependent.  Brit J Pharmacol 100:435-440, 1990

Kaplan GB, Tai NT, Greenblatt DJ, Shader RI.  Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo.   Psychopharmacology 101:539-544, 1990

Lopez F, Miller LG, Greenblatt DJ, Kaplan GB, Shader RI.  Interaction of caffeine with the GABAA receptor complex: alterations in receptor function but not ligand binding.  Eur J Pharmacol 172:453-459, 1989

Kaplan GB, Greenblatt DJ, LeDuc BW, Thompson ML, Shader RI.  Relationship of plasma and brain caffeine metabolites to benzodiazepine receptor binding and locomotor activity.  J Pharmacol Exp Ther 248:1078-1083, 1989

Arana GW, Kaplan GB.  Trazodone-induced mania following desipramine-induced mania in major depressive disorders.  Am J Psychiatry 142:386, 1985

Clark CC, Crossland J, Kaplan G, Martinez-Hernandez, A.  Location and identification of the collagen found in the 14.5-d rat embryo visceral yolk sac. J Cell Biology 93:251-260, 1982